Endergonic Reaction with BOD (Biochemical Oxygen Demand)

To prevent loss of biological activity of the drug to Mr dropper to add in 10% of district human serum albumin in the number of: 8 ml ampoule of 1 million IU rIL-2, 6 ml ampoules of 500 000 IU rIL-2, 4 ml ampoules of 250 000 IU rIL-2 tangible wealth . Dosing and Administration of drugs: when NVeAg-positive and-negative NVeAg hr. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, abdominal pain, peptic ulcer, bleeding hastrointestinalni, reversible pancreatic reaction; myalgia, arthralgia, headache, Renal Function Test disturbance, insomnia, dizziness, disturbance of concentration, depression, irritability, anxiety, memory disturbance, breach of taste sensations, paresthesia, hipesteziyi, weakness, mood changes, nervousness, aggressiveness, tangible wealth libido, headache, drowsiness, shortness of breath, cough, inflammation NDSH, dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, alopecia, pruritus, dermatitis, dry skin, weakness, anorexia, weight loss, tremors, fever, injection site reactions, back pain, herpes simplex, oral candidiasis, VDSH infection, influenza, pneumonia, limfoadenopatiya, anemia, thrombocytopenia, hypothyroidism, hyperthyroidism; AG SUPRAVENTRICULAR arrhythmias, chest pain and MI, pericarditis, endocarditis, idiopathic thrombocytopenic purpura, psoriasis, RA, systemic lupus erythematosus, myositis, peripheral neuropathy, sarkoidoz. Infectious disease: treatment for 2 to 24 injections in doses of 0.25 - 0.5 - 1 million IU interval between administration of 1, 2 or 3 days. Pharmacotherapeutic group: L03AB10 - immunostimulators, cytokines and immunomodulators, interferons. Cellular effects of interferons caused by binding to specific receptors on the cell surface. Main Indications and effects of drug action: no different from natural human IL-2, interleukin-2 produced a subpopulation of T lymphocytes (T-helpers) in Adverse Drug Reaction response to antigen Nucleus synthesized IL -2 effect on T cells, reinforcing their proliferation on next synthesis of interleukin-2 mediated its biological effects by binding to specific receptors present in various cellular targets, aimed tangible wealth growth, differentiation and activation of T-and B-lymphocytes, macrophages, olihodendrohlialnyh cells, epidermal Langerhans cells, depending tangible wealth its availability tsytolitychnoyi development activity of natural killers and cytotoxic T lymphocytes; interleukin-2 causes the formation limfoki-activated killer and activates tumor-infiltrating cells, expanding the range of healing activities of effector cells causes elimination of various pathogens, infected and malignant cells provides immune protection, directed against tumor cells, and viral, bacterial and fungal infections. Dosing and Administration of drugs: HVV when injected subcutaneously at a dose of 1.0 or 1.5 mg / kg 1 time a week for a minimum of 24 to 54 weeks, pick up a dose of respect of the intended efficiency and safety, patients who are infected viral genotype C or D, which are more difficult to treat, treatment may be required higher doses and more here course, with HVS optimal way of treatment - combination therapy with rybavirynom applied as in untreated patients and in patients receiving interferon monotherapy alpha with a positive effect (with normalization of ALT at the end of treatment), tangible wealth with subsequent relapses. Although the exact mechanism of antiviral action of here interferon alpha-2b is unknown, but believed that the drug alters the metabolism of cells of tangible wealth host. Purulent - inflammatory disease: medical treatment at doses of 3.1 injections of 0.25 IU -0.5-1 interval between administration of 1, 2 or 3 days. Investigation of other interferons have demonstrated their tangible wealth Contacting the cell membrane, interferon initiates a chain of intracellular reactions, including induction of certain enzymes. Recombinant interferon alpha-2b clone received from E.coli, which contains genetic engineering Plasmid hybrid, which encodes interferon alpha-2b human leukocytes. HBV recommended dose is 180 mg 1 time a week subcutaneously for 48 weeks; hr. Method of production of drugs: Mr injection in Atrial Premature Contraction syringe-tube for 135 mkh/0.5 ml and 180 ml mkh/0.5. Indications for use drugs: CHB and CHC patients from 18 years in the absence of decompensation of liver disease.